Phase 3 trial is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-07. Numbers and descriptions here follow the published literature rather than marketing material.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
(123Te is expected to decay to 123Sb, but the half-life appears to be so long that the decay has never been observed.) There are no stable nuclides having atomic number greater than Z = 82 (lead), although bismuth (Z = 83) is stable for all practical human purposes, and thorium (Z = 90) and uranium (Z = 92) are sufficiently long-lived to occur on Earth in large quantities. Elements with atomic numbers from 1 to 82 all have stable isotopes, with the exceptions of technetium (Z = 43) and promethium (Z = 61).
=== Post-mastectomy procedures === Surgical post-mastectomy breast reconstruction requires general anaesthesia, cuts the chest muscles, produces new scars, and requires a long post-surgical recovery for the patient. The surgical emplacement of breast implant devices (saline or silicone) introduces a foreign object to the patient's body (see capsular contracture). The TRAM flap (Transverse Rectus Abdominis Myocutaneous flap) procedure reconstructs the breast using an autologous flap of abdominal, cutaneous, and muscle tissues. The latissimus myocutaneous flap employs skin fat and muscle harvested from the back, and a breast implant. The DIEP flap (Deep Inferior Epigastric Perforators) procedure uses an autologous flap of abdominal skin and fat tissue.
Injury: A mild form of myositis can occur with hard exercise. A more severe form of muscle injury, called rhabdomyolysis, is also associated with myositis. This is a condition where an injury to the patient's muscles causes them to quickly break down. Medicines: A variety of different medicines can cause myositis. One of the most common types of drugs that can cause myositis are statins, which are used to lower cholesterol levels. One of the most common side effects of statin therapy is muscle pain which, more rarely, can lead to myositis. Infection: The most common infectious cause of myositis is viral infections, such as the common cold. Other viruses, such as COVID-19, are also shown to be a rare cause of myositis. Benign acute childhood myositis has been described in children after prodromal viral infections with different viral agents. Bacterial, parasitic, and fungal infections are other infectious causes of myositis. Inherited muscle disease: Many inherited myopathies may have secondary myositis, including calpainopathy, dysferlinopathy, facioscapulohumeral muscular dystrophy, dystrophinopathy, and LMNA-associated myopathy. Autoimmune: Autoimmune disease is an abnormal immune response to specific body protein or other biomolecular target, such as one of the muscles. The three main types of idiopathic myositis (known as inflammatory myopathies) that typically test positive for autoantibodies are dermatomyositis, polymyositis, and inclusion body myositis. Other autoimmune diseases, such as systemic lupus erythematosus, can also cause myositis-like symptoms.
The mine chose to send all ore to the crusher and to concentrate on copper production due to the rising price of copper on the world market. The price of natural untreated Sleeping Beauty turquoise has risen dramatically since the mine's closing. The Kingman Mine as of 2015 still operates alongside a copper mine outside of the city. Other mines include the Blue Bird mine, Castle Dome, and Ithaca Peak, but they are mostly inactive due to the high cost of operations and federal regulations. The Phelps Dodge Lavender Pit mine at Bisbee ceased operations in 1974 and never had a turquoise contractor. All Bisbee turquoise was "lunch pail" mined. It came out of the copper ore mine in miners' lunch pails. Morenci and Turquoise Peak are either inactive or depleted. Nevada is the country's other major producer, with more than 120 mines which have yielded significant quantities of turquoise. Unlike elsewhere in the US, most Nevada mines have been worked primarily for their gem turquoise and very little has been recovered as a byproduct of other mining operations. Nevada turquoise is found as nuggets, fracture fillings and in breccias as the cement filling interstices between fragments. Because of the geology of the Nevada deposits, a majority of the material produced is hard and dense, being of sufficient quality that no treatment or enhancement is required. While nearly every county in the state has yielded some turquoise, the chief producers are in Lander and Esmeralda counties.
Sources: en.wikipedia.org
Kardashev mentions another hypothesis that, in his opinion, is capable of explaining the dynamics of the supercivilizations: the "feedback effect" (theorized by Sebastian von Hoerner in 1975), which is based on the hypothesis that at a high technological level, civilizations tend to converge rather than to isolate themselves. The distance between supercivilizations could then be determined by half the time of the technological evolution of the oldest civilization, which would be about 3 to 4 billion years. On the other hand, this supercivilization may not have been present in our galaxy for a long time. Kardashev concludes by saying that since the expansion of the Universe is infinite, the number and lifetime of such supercivilizations are also infinite.
== In fossils == In 2016, scientists reported the discovery of an osteosarcoma tumor in a 1.6–1.8 million-year-old fossil from the skeleton of the now-extinct hominin species Australopithecus sediba, making it the earliest-known case of human cancer.
== Bibliography == Greenwood, Norman N.; Earnshaw, Alan (1997). Chemistry of the Elements (2nd ed.). Butterworth–Heinemann. ISBN 978-0080379418. Haire, Richard G. (2006). "Einsteinium". In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements (PDF). Vol. 3 (3rd ed.). Dordrecht, the Netherlands: Springer. pp. 1577–1620. doi:10.1007/1-4020-3598-5_12. ISBN 978-1-4020-3555-5. Archived from the original (PDF) on 2010-07-17. Holleman, Arnold F. & Wiberg, Nils (2007). Textbook of Inorganic Chemistry (102nd ed.). Berlin: de Gruyter. ISBN 978-3-11-017770-1. Seaborg, G.T., ed. (23 January 1978). Proceedings of the Symposium Commemorating the 25th Anniversary of Elements 99 and 100 (PDF). Report LBL-7701.
=== „Sozusagen Paris“ (2016) === „Sozusagen Paris“' (Paris, So to Speak) constitutes a sequel to the previous novel: after a public reading from „Love Writ Large“, the first-person narrator is approached by his childhood sweetheart, who is now the mayor of a small town. This sequel describes the first encounter between the two characters after thirty years, which lasts from the moment of their reunion after the public reading until the next morning. Overall, the text complements its predecessor: whereas the former dealt with the ecstasy of first love, the latter focuses on long-term love, specifically in light of Jutta's 23-year marriage. Whereas „Love Writ Large“ was told from the man's perspective, the nighttime conversation in Paris, So to Speak is shaped by the woman’s point of view —for the first time in Kermani's work, a female voice is at the center of the text. Like „Love Writ Large, Paris So to Speak“ also aims at a supra-individual exploration of love, but it is anchored differently: instead of early Islamic mysticism, it’s the French marriage novels of the nineteenth century up to Marcel Proust which serve as a foil here for modern love. This shifts the reflection on love from a general anthropological to a historical perspective. In particular, the important role of their children to the couple's life, lifestyle, and emotional stability serves to emphasize distinctions from older marriage novels and to highlight specifics of love and cohabitation in the 21st century.
Physical-chemical testing; Toxicity studies; Mutagenicity studies; Environmental toxicity studies on aquatic and terrestrial organisms; Studies on behavior in water, soil, and air; bioaccumulation; Studies to determine pesticide residues in food or animal feedstuffs; Studies on effects on mesocosms and natural ecosystems; Analytical and clinical chemistry testing. Safety testing data must be submitted to regulatory authorities for product marketing authorization. During the review process, the submitted data undergoes verification to ensure compliance with GLP standards. Additionally, the GLP compliance status of the testing facility where the study was conducted is assessed by referring to inspection information from national GLP compliance monitoring programs. OECD member countries where non-clinical health and environmental safety testing follows the OECD Principles of Good Laboratory Practice (GLP) have established national GLP Compliance Monitoring Programs (CMP) responsible for overseeing GLP compliance of test facilities within their jurisdictions. These CMPs verify GLP compliance through inspections of test facilities and audits of GLP studies. Test facilities that undergo periodic inspections by a CMP and are found to operate in accordance with GLP principles are recognized as GLP compliant. In OECD-member countries, testing facilities seeking recognition as GLP compliant can apply to the national CMP. The CMP then conducts inspections to assess if the test facility adheres to the OECD Principles of GLP.
Sources: en.wikipedia.org
== Pharmacology == Rimonabant is an inverse agonist of the cannabinoid CB1 receptor. Originally thought to be selective for the CB1 receptor, rimonabant was subsequently also found to act as an antagonist of the μ-opioid receptor. These properties may make this drug useful in cases of cannabinoid or opioid overdose but more research and safety testing is required.
== Formation == A glucuronosyltransferase enzyme UGT2B7 present in human liver converts codeine to its glucuronide by adding a sugar acid at the hydroxy group, with uridine diphosphate (UDP) as byproduct:
== Origins == The word metabolome appears to be a blending of the words "metabolite" and "chromosome". It was constructed to imply that metabolites are indirectly encoded by genes or act on genes and gene products. The term "metabolome" was first used in 1998 and was likely coined to match with existing biological terms referring to the complete set of genes (the genome), the complete set of proteins (the proteome) and the complete set of transcripts (the transcriptome). The first book on metabolomics was published in 2003. The first journal dedicated to metabolomics (titled simply "Metabolomics") was launched in 2005 and is currently edited by Prof. Roy Goodacre. Some of the more significant early papers on metabolome analysis are listed in the references below.
=== Fusimotor system === Muscle spindles relay information to the CNS via afferents, and they receive efferent signals from the spinal cord via gamma fusimotor neurons. This gamma innervation modulates the sensitivity of muscle spindle afferents to stretch. Gamma motoneurons are categorized according to the static and dynamic response properties of the muscle spindle afferents they affect. In recordings with semi-microelectrodes inserted into peripheral nerves in humans, muscle spindle afferent firing rates increased during muscle contraction. This suggested that gamma motoneuronal activity was linked to alpha motoneuronal activity (alpha-gamma co-activation). Only small movements were studied because electrodes otherwise dislodged. In studies of locomotion in decerebrate cats, gamma activity was shown to be correlated with cyclical variations in joint angle. In cats performing normal walking, beam-walking, landing from falls and resisting imposed movement, the mean firing rates of muscle spindle primary afferents and their sensitivity to variations in muscle length changed according to task. Sensitivity greatly increased in difficult tasks and in states of vigilance, presumably due to increases in dynamic gamma activity. The terms fusimotor "wind-up" and fusimotor "set" were coined to describe these behaviors.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.